drugset
drugset / Trial / NCT06395155

A Phase 1 Clinical Trial DHP2306R1 and DHP2306R2 in Healthy Adult Volunteers

NCT06395155 ↗

Phase 1 Completed 54 enrolled Daehwa Pharmaceutical Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This phase 1 study is to evaluate the safety and pharmacokinetic drug interactions of DHP2306R1 and DHP2306R2 when administered alone and in combination in healthy conditions. Participants will be taken DHP2306R1 and DHP2306R2 alone or combination for 3 period, randomized in six-sequence.

Timeline

Start
2023-10-26
Primary completion
2023-12-07
Completion
2023-12-07

Drugs

EvaluationDrugModalityDoseRoute
Subject DHP2306R1 Unknown 100 mg —
Subject DHP2306R2 Unknown 75 mg —

Indications

musculoskeletal system disorder